US.INCY · Incyte

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 3.004237662223007,
        "turnoverUsdM": 219.79896248999998,
        "liquidityPoints": 0.4,
        "volatilityPoints": 0.7
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.INCY",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 106.4642,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 1,
        "rsi_score": 2.5,
        "macd_score": 1,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 6,
      "take_profit_price": 119.7355,
      "target_multiplier": 1.9,
      "technical_strength": 1.5,
      "take_profit_percent": 5.7
    },
    "positionPoints": 1.1,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 6.008475324446014,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 52.8,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 45.8,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 118.1165,
    "ma50": 121.9402,
    "close": 113.27,
    "prevClose": 111.57,
    "avgVolume20": 1833789,
    "volumeRatio": 1.06,
    "changePercent": 1.52
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.004611973392461222,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 1.0719708541297808,
      "ret_points": 4,
      "vol_points": 2,
      "range_ratio": 1.0891732003619725,
      "volat_points": 0,
      "day_range_pct": 0.03028161914010779,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 52.8,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 100,
        "contribution": 5
      },
      {
        "raw": 8.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 42,
        "contribution": 8.4
      },
      {
        "raw": 8.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 57.33,
        "contribution": 8.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.3,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 63,
        "contribution": 6.3
      },
      {
        "raw": 11.5,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 38.33,
        "contribution": 11.5
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 45.8,
    "details": [
      "基本面分析總分: 5/5分",
      "資金流分析總分: 8.4/20分",
      "市場環境分析總分: 8.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.3/10分",
      "技術信號分析總分: 11.5/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 5,
      "資金流": 8.4,
      "市場環境": 8.6,
      "情緒分析": 4,
      "技術信號": 11.5,
      "風險管理": 6.3
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.5,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 219.79896248999998,
          "volumePoints": 0.5,
          "revenuePoints": 0.75,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 0.8,
          "obvPoints": 4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.INCY",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.87
            }
          },
          "trend": {
            "score": 3.4,
            "details": {
              "qqq": {
                "ma20": 743.10150415,
                "ma50": 726.8704012600002,
                "name": "QQQ",
                "close": 728,
                "points": 1.4
              },
              "spy": {
                "ma20": 771.10599665,
                "ma50": 768.6079965800001,
                "name": "SPY",
                "close": 771.78998,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 3.004237662223007,
          "atrPoints": 2,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 3.4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142562095,
                "url": "https://finnhub.io/api/news?id=4475fc6448f9a8a411761970f0b1b559fc63c7dee7dd75dda31557be570b512d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q2, starting with Incyte (NASDAQ:INCY).",
                "category": "company",
                "datetime": 1790883187,
                "headline": "Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment"
              },
              {
                "id": 142521143,
                "url": "https://finnhub.io/api/news?id=d0d36b7cd2ff25dc25a458e3cd0397722758290b66be7129ef682d8beb405b0f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "INCY vs. TECH: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1790779202,
                "headline": "INCY or TECH: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142512990,
                "url": "https://finnhub.io/api/news?id=ebb9e8bd99a1dd17ab44f34bc85f9b82e7d59f57be8b09a67242ba3f904b7872",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY stock clears high growth momentum and technical screens with strong EPS growth, rising margins, and a constructive chart setup near a potential breakout.",
                "category": "company",
                "datetime": 1790768482,
                "headline": "Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout Setup"
              },
              {
                "id": 142425658,
                "url": "https://finnhub.io/api/news?id=6b7cf0c329c8dc9bb5e2734373f8103650936b92a03c025e34b722532dbf4167",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The Food and Drug Administration’s target date is Saturday, September 26, for zilurgisertib, a once-daily pill for fibrodysplasia ossificans progressiva, or FOP, in patients 12 and older.",
                "category": "company",
                "datetime": 1790361817,
                "headline": "INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill"
              },
              {
                "id": 142385866,
                "url": "https://finnhub.io/api/news?id=3828c89500c6869d3d4411c2f0c78565aac49ea0090f122d899558790e68480b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte has delivered a strong multi year share-price run, so the obvious follow up is whether the current valuation is still grounded in the cash the business is expected to generate. With investors weighing fresh product news against a higher starting price, the question is how much of Incyte's future cash flows are already embedded in today's quote. Over the past 3 years the stock has gained 110.9%, which puts pressure on investors to judge whether the cash flow outlook has risen enough to...",
                "category": "company",
                "datetime": 1790273697,
                "headline": "Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data"
              },
              {
                "id": 142366686,
                "url": "https://finnhub.io/api/news?id=1b4559feffaf16a0ad76e770037599887130cf9a4c4f286289b8055186edae2f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NasdaqGS: INCY) plans to present new clinical data on its inflammation and autoimmunity portfolio at the upcoming EADV Congress. The presentation will spotlight updates for Opzelura, ruxolitinib cream, across immune mediated skin diseases studied in recent dermatology trials. Incyte will also feature new findings on povorcitinib, reflecting progress across multiple dermatological indications under investigation. These fresh EADV data drops on Opzelura and povorcitinib only tell part...",
                "category": "company",
                "datetime": 1790212531,
                "headline": "Incyte (INCY) Heads To EADV With New Skin Disease Trial Data"
              },
              {
                "id": 142310717,
                "url": "https://finnhub.io/api/news?id=2094a2c5f9c153b52aeda12f343c88808922fee79702e16bb8ec9cad1deb9cd3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.",
                "category": "company",
                "datetime": 1789988803,
                "headline": "FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week"
              },
              {
                "id": 142251199,
                "url": "https://finnhub.io/api/news?id=a581129efd1456cf0c04bbcd52a533fb0e0cec3f6e1787c33892f5e1d2478b14",
                "image": "https://www.chartmill.com/images/uploads/minervini_news_8825971f4b.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY combines Minervini Trend Template strength, 93.53 RS, and high-growth momentum. Technical Rating 9, but watch resistance near 129.93 for breakout.",
                "category": "company",
                "datetime": 1789729273,
                "headline": "Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum"
              }
            ],
            "raw_source": [
              {
                "id": 142918121,
                "url": "https://finnhub.io/api/news?id=0c60b7251adfe2eb346ee7992ddbd59053c051aa0e0a3820ebbfd95d49f0a24f",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Truist Securities  analyst Srikripa Devarakonda   maintains Incyte (NASDAQ:INCY) with a Hold and raises the price target from $105 to $115.",
                "category": "company",
                "datetime": 1791984605,
                "headline": "Truist Securities Maintains Hold on Incyte, Raises Price Target to $115"
              },
              {
                "id": 142848926,
                "url": "https://finnhub.io/api/news?id=9a21bc6679040d47af2b097ddec1264df35938cafcc4522683542e78d36acb1c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), announced that Ming Wang (CEO) will participate in Boston CEO, November 2-3, 2026, at the Mandarin Oriental Hotel in Boston, MA. He will speak on a discussion panel entitled Competing in a New Global Playing Field.",
                "category": "company",
                "datetime": 1791896520,
                "headline": "Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026"
              },
              {
                "id": 142850332,
                "url": "https://finnhub.io/api/news?id=50d834f420411987405f297f0986958a6aa7e034de3dbdf9361db3bcef17ae1f",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "HC Wainwright & Co.  analyst Mitchell S. Kapoor   reiterates Incyte (NASDAQ:INCY) with a Buy and maintains $152 price target.",
                "category": "company",
                "datetime": 1791873418,
                "headline": "HC Wainwright & Co. Reiterates Buy on Incyte, Maintains $152 Price Target"
              },
              {
                "id": 142824238,
                "url": "https://finnhub.io/api/news?id=bacaa0760479e8077018a44bda1ddb5821f5553ec0790d93f15b431d02fb26f7",
                "image": "https://www.chartmill.com/images/uploads/CM_Aftermarket_Movers_Small_free_e077945a19.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "After the closing bell on Monday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session.",
                "category": "company",
                "datetime": 1791839101,
                "headline": "Discover the top S&P500 movers in Monday's after-hours session."
              },
              {
                "id": 142764205,
                "url": "https://finnhub.io/api/news?id=78f2a1b20a92c2f2664cbf93a4df03d907ffde640be59eabf97e4f652329c59c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Vertex Pharmaceuticals (VRTX) stock trades at 29.0 times earnings. That valuation prices the company higher than Regeneron and Incyte, two of its biotech peers. Vertex does generate the highest operating margin among its group of five companies, but its sales are growing more slowly than at three of the other four. So how much more are you paying for Vertex, and what do you get for it.",
                "category": "company",
                "datetime": 1791560209,
                "headline": "Is Vertex Stock Worth More Than Its Competitors?"
              },
              {
                "id": 142765501,
                "url": "https://finnhub.io/api/news?id=36685ffd3e97ab8486e6f47bfc46d2ef5b32cd0ec6791a1304605903a25a0dcc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte will report its third-quarter earnings soon, with analysts forecasting a steep triple-digit plunge in its bottom line compared with the year-ago quarter.",
                "category": "company",
                "datetime": 1791542538,
                "headline": "What to Expect From Incyte’s Next Quarterly Earnings Report"
              },
              {
                "id": 142727790,
                "url": "https://finnhub.io/api/news?id=2bfd1260a045cbe27416cef5f31ccc79995d53168e565cea6a6d4091f496879d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., October 08, 2026--3Q26 Earnings Announcement",
                "category": "company",
                "datetime": 1791460800,
                "headline": "Incyte to Report Third Quarter Financial Results"
              },
              {
                "id": 142728523,
                "url": "https://finnhub.io/api/news?id=4ac2c471ac34036e3b4008229d81fb13b326c1db44af51577b296f015cd224b9",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Incyte (NASDAQ:INCY) with a Sector Perform and raises the price target from $109 to $114.",
                "category": "company",
                "datetime": 1791453844,
                "headline": "RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $114"
              },
              {
                "id": 142728524,
                "url": "https://finnhub.io/api/news?id=765938f016dda6652337e3c2097f957bd9f125fe38be302d57ab41e9d3146b45",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) has outperformed the market over the past 15 years by 1.22% on an annualized basis producing an average annual return of 14.45%. Currently, Incyte has a market capitalization of $22.70 billion.",
                "category": "company",
                "datetime": 1791395120,
                "headline": "If You Invested $1000 In Incyte Stock 15 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 142662169,
                "url": "https://finnhub.io/api/news?id=d3f58a3ce0b6e2bf9f405a09dff1ad258cfd1f49c4f14b7aa009c191bf96a04f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (\"Knight\") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1 “For patients living with chronic",
                "category": "company",
                "datetime": 1791286500,
                "headline": "Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil"
              },
              {
                "id": 142636275,
                "url": "https://finnhub.io/api/news?id=074b879f086129c8c62250751445aac9ea31a435c0d99b017957e8be236fa113",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Stifel  analyst Stephen Willey   maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $145 to $157.",
                "category": "company",
                "datetime": 1791184316,
                "headline": "Stifel Maintains Buy on Incyte, Raises Price Target to $157"
              },
              {
                "id": 142562095,
                "url": "https://finnhub.io/api/news?id=4475fc6448f9a8a411761970f0b1b559fc63c7dee7dd75dda31557be570b512d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q2, starting with Incyte (NASDAQ:INCY).",
                "category": "company",
                "datetime": 1790883187,
                "headline": "Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment"
              },
              {
                "id": 142588720,
                "url": "https://finnhub.io/api/news?id=cf47e1d66b6cbc95eefdae0dd23bf89024b00365a4523494f88a0fe630bacc8b",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.48% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of $23.82 billion.",
                "category": "company",
                "datetime": 1790877638,
                "headline": "If You Invested $1000 In Incyte Stock 20 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 142557475,
                "url": "https://finnhub.io/api/news?id=d651d67aff3fb4f7e7c9ca6edda101b005d21406b80e151cc62e9a1a8627ec8e",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Wells Fargo  analyst Derek Archila   maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $116 to $128.",
                "category": "company",
                "datetime": 1790843575,
                "headline": "Wells Fargo Maintains Equal-Weight on Incyte, Raises Price Target to $128"
              },
              {
                "id": 142521143,
                "url": "https://finnhub.io/api/news?id=d0d36b7cd2ff25dc25a458e3cd0397722758290b66be7129ef682d8beb405b0f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "INCY vs. TECH: Which Stock Is the Better Value Option?",
                "category": "company",
                "datetime": 1790779202,
                "headline": "INCY or TECH: Which Is the Better Value Stock Right Now?"
              },
              {
                "id": 142512990,
                "url": "https://finnhub.io/api/news?id=ebb9e8bd99a1dd17ab44f34bc85f9b82e7d59f57be8b09a67242ba3f904b7872",
                "image": "https://www.chartmill.com/images/uploads/HGM_Breakout_19d1a7df53.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY stock clears high growth momentum and technical screens with strong EPS growth, rising margins, and a constructive chart setup near a potential breakout.",
                "category": "company",
                "datetime": 1790768482,
                "headline": "Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout Setup"
              },
              {
                "id": 142468441,
                "url": "https://finnhub.io/api/news?id=c66772dfe3ee69a70fa76f2ec8797d2c4507466e9205bbc48d9e0224ef01e94c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.",
                "category": "company",
                "datetime": 1790606700,
                "headline": "MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy"
              },
              {
                "id": 142468169,
                "url": "https://finnhub.io/api/news?id=9ad50950f9b05da2510f7ec51b6f364ba10619157b26b3adf3c6882330aaa6d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Eli Lilly's Olumiant wins FDA nod to treat pediatric patients 12 years of age and older with severe alopecia areata, expanding its U.S. use after strong phase III results.",
                "category": "company",
                "datetime": 1790604180,
                "headline": "LLY's Olumiant Gets FDA Nod for Expanded Use in Pediatric Hair Loss"
              },
              {
                "id": 142496785,
                "url": "https://finnhub.io/api/news?id=b0321508ca7458c7703eb8f5a78166f3b934a58362f2be1e62b5becfdf34fc96",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "JP Morgan  analyst Jessica Fye   maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $120 to $123.",
                "category": "company",
                "datetime": 1790602585,
                "headline": "JP Morgan Maintains Neutral on Incyte, Raises Price Target to $123"
              },
              {
                "id": 142496786,
                "url": "https://finnhub.io/api/news?id=955439cb6c2933ce5d22d366515ce2ead7b8027540c649b33b1e2244368d4cf6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/28/Balding-Man-Showing-His-Head-With-Thin-H.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "FDA approves Eli Lilly's once-daily pill Olumiant for adolescents aged 12 and older with severe alopecia areata following Phase 3 trials.",
                "category": "company",
                "datetime": 1790600073,
                "headline": "FDA Expands Approval Of Eli Lilly's Olumiant For Adolescents with Autoimmune Hair Loss"
              },
              {
                "id": 142466645,
                "url": "https://finnhub.io/api/news?id=12d9e67f1e1f5fb300b04e70799f6f27112241cb27815fdc45b06f74553858db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The U.S. Food and Drug Administration (FDA) on Friday approved Atebrioz (zilurgisertib) tablets, delivering a new once-daily oral treatment to patients suffering from fibrodysplasia ossificans progressiva (FOP). Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) and Incyte Corporation (NASDAQ:INCY) announced the regulatory milestone, noting the medication helps reduce the volume of new abnormal bone formation in adults and children aged 12 and older. Read Also: Regeneron Secures FDA Approval For Ultra-Rar",
                "category": "company",
                "datetime": 1790599105,
                "headline": "Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment"
              },
              {
                "id": 142467335,
                "url": "https://finnhub.io/api/news?id=78bdb57e04871ecb34909a65606c74a31535191982b93c57cba49eb178fbc568",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "HC Wainwright & Co.  analyst Mitchell S. Kapoor   maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $150 to $152.",
                "category": "company",
                "datetime": 1790576925,
                "headline": "HC Wainwright & Co. Maintains Buy on Incyte, Raises Price Target to $152"
              },
              {
                "id": 142463061,
                "url": "https://finnhub.io/api/news?id=ec1a24189f67ee162e36de4447d0ec890cc341b591464fb0ec8cbadece6aa492",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2295578501/image_2295578501.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Syndax achieved FDA approval for Revuforj in r/r mNPM1 AML and is pursuing pivotal studies to expand into 1st-line AML populations. Read why SNDX is a Strong Buy.",
                "category": "company",
                "datetime": 1790572953,
                "headline": "Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases"
              },
              {
                "id": 142427042,
                "url": "https://finnhub.io/api/news?id=35a7a53435f6293704a9963de0e5dbe152bf4b44a46b7ad6f183aa81df7508ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "FOSTER CITY, Calif. & WILMINGTON, Del., September 25, 2026--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva",
                "category": "company",
                "datetime": 1790377200,
                "headline": "Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva"
              },
              {
                "id": 142425658,
                "url": "https://finnhub.io/api/news?id=6b7cf0c329c8dc9bb5e2734373f8103650936b92a03c025e34b722532dbf4167",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The Food and Drug Administration’s target date is Saturday, September 26, for zilurgisertib, a once-daily pill for fibrodysplasia ossificans progressiva, or FOP, in patients 12 and older.",
                "category": "company",
                "datetime": 1790361817,
                "headline": "INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill"
              },
              {
                "id": 142437357,
                "url": "https://finnhub.io/api/news?id=87de46760052dac2d262596b39e8957ee92e0233ae78bcefc82787bc209b1f20",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-third-treatment-fibrodysplasia-ossificans-progressiva",
                "category": "company",
                "datetime": 1790348028,
                "headline": "FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily"
              },
              {
                "id": 142385866,
                "url": "https://finnhub.io/api/news?id=3828c89500c6869d3d4411c2f0c78565aac49ea0090f122d899558790e68480b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte has delivered a strong multi year share-price run, so the obvious follow up is whether the current valuation is still grounded in the cash the business is expected to generate. With investors weighing fresh product news against a higher starting price, the question is how much of Incyte's future cash flows are already embedded in today's quote. Over the past 3 years the stock has gained 110.9%, which puts pressure on investors to judge whether the cash flow outlook has risen enough to...",
                "category": "company",
                "datetime": 1790273697,
                "headline": "Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data"
              },
              {
                "id": 142366686,
                "url": "https://finnhub.io/api/news?id=1b4559feffaf16a0ad76e770037599887130cf9a4c4f286289b8055186edae2f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NasdaqGS: INCY) plans to present new clinical data on its inflammation and autoimmunity portfolio at the upcoming EADV Congress. The presentation will spotlight updates for Opzelura, ruxolitinib cream, across immune mediated skin diseases studied in recent dermatology trials. Incyte will also feature new findings on povorcitinib, reflecting progress across multiple dermatological indications under investigation. These fresh EADV data drops on Opzelura and povorcitinib only tell part...",
                "category": "company",
                "datetime": 1790212531,
                "headline": "Incyte (INCY) Heads To EADV With New Skin Disease Trial Data"
              },
              {
                "id": 142358803,
                "url": "https://finnhub.io/api/news?id=87962f9bb4b6eb0c25e3cfa1c05685a4b675d266644338f9cd62473a6e65ac29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.",
                "category": "company",
                "datetime": 1790166480,
                "headline": "6 ‘Moonshot’ Biotech Stocks That Offer Big Risks, Bigger Rewards"
              },
              {
                "id": 142356861,
                "url": "https://finnhub.io/api/news?id=048dae12c884c5440778165c65832d70813661cfd4f68efa558a277404fa1656",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte is gaining momentum, recently outperforming the biotech sector and keeping analysts broadly positive on the stock.",
                "category": "company",
                "datetime": 1790139185,
                "headline": "How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?"
              },
              {
                "id": 142341008,
                "url": "https://finnhub.io/api/news?id=e07509feed6d582176ea1f7022d5ccea2fd1c29852470c7fb6a1daa1f4c136f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Dow Jones tech titan Amazon stock is battling with a key support level and approaching multiple new buy points.",
                "category": "company",
                "datetime": 1790098003,
                "headline": "Dow Jones Tech Titan Amazon Eyes Buy Point Amid Battle With Key Support Level"
              },
              {
                "id": 142340116,
                "url": "https://finnhub.io/api/news?id=aeed3fe8849fb6aa28c94f0efc6389f48c242be154e36226fb51b45dc7c367d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte's (INCY) colorectal cancer or CRC programs remain \"risky and more long-term,\" RBC Capital Mar",
                "category": "company",
                "datetime": 1790091909,
                "headline": "Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says"
              },
              {
                "id": 142337151,
                "url": "https://finnhub.io/api/news?id=ec15db9f3538528033e3a2b785c80a05463d3015aa798d3d099f3d82dfb34f1d",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "Get insights into the top gainers and losers in the S&P500 index of Tuesday's pre-market session.",
                "category": "company",
                "datetime": 1790080501,
                "headline": "Discover the top S&P500 movers in Tuesday's pre-market session."
              },
              {
                "id": 142338131,
                "url": "https://finnhub.io/api/news?id=29b6ec4222978b9a1e65396ac18d0b1804ad3eb89b0343b51086c32382719d8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "WILMINGTON, Del., September 22, 2026--Incyte Data at the 2026 EADV Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio",
                "category": "company",
                "datetime": 1790080200,
                "headline": "Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio"
              },
              {
                "id": 142339322,
                "url": "https://finnhub.io/api/news?id=5e344a9f1bd46602f68ceaf49af71aeba9068605f9fd8987d1e69965ab956e21",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "RBC Capital  analyst Brian Abrahams   reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $109 price target.",
                "category": "company",
                "datetime": 1790069064,
                "headline": "RBC Capital Reiterates Sector Perform on Incyte, Maintains $109 Price Target"
              },
              {
                "id": 142339323,
                "url": "https://finnhub.io/api/news?id=59f827cac6ca47941028081fa6c55528b3d2815a1bbfe015fa3e3a79400bc8f5",
                "image": "",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "Oral PresentationsAtopic DermatitisAtopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL)(Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October",
                "category": "company",
                "datetime": 1790066161,
                "headline": "Incyte To Present Data From Its Inflammation And Autoimmunity Portfolio At The European Academy Of Dermatology And Venereology Conference, September 30-October 3"
              },
              {
                "id": 142338042,
                "url": "https://finnhub.io/api/news?id=5fbe59656eb7c8e519203883d87a9ba7e725d627ad9c93744d9bd2b9cb6b416c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/22/Stockholm--Sweden---October-8--2021-An-O.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.",
                "category": "company",
                "datetime": 1790064067,
                "headline": "Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session"
              },
              {
                "id": 142310717,
                "url": "https://finnhub.io/api/news?id=2094a2c5f9c153b52aeda12f343c88808922fee79702e16bb8ec9cad1deb9cd3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.",
                "category": "company",
                "datetime": 1789988803,
                "headline": "FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week"
              },
              {
                "id": 142291354,
                "url": "https://finnhub.io/api/news?id=1e8e127ca473ed1c75eed9faf8ea2c32eb99dfeff39a2f89f8005a159838fe5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences International, an affiliate of Incyte (NASDAQ: INCY), to commercialise, distribute, and register ruxolitinib cream (registered as Opzelura® in the U.S. and European Union) in Australia.",
                "category": "company",
                "datetime": 1789934400,
                "headline": "Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia"
              },
              {
                "id": 142277352,
                "url": "https://finnhub.io/api/news?id=fa32183130775dd71561fd6fc458532c82f005b944d06280d442f2121a70a101",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (NASDAQ:INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029. Chief Executive Officer Bill Meury said the company’s pipeline has changed substantially over t",
                "category": "company",
                "datetime": 1789869726,
                "headline": "Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target"
              },
              {
                "id": 142270936,
                "url": "https://finnhub.io/api/news?id=64ab13c25410463853c539597d8b85ea92d766443816efe08bdfb20887bc0cba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Robinhood stock surged in an end-of-week crypto rally. SpaceX is testing an aggressive entry. They lead five stocks near buy points.",
                "category": "company",
                "datetime": 1789819239,
                "headline": "Robinhood Soars, SpaceX Orbits Entry: Five Stocks Near Buy Points"
              },
              {
                "id": 142260296,
                "url": "https://finnhub.io/api/news?id=a8f8b27d7a050cf25b8b0188ed53de38748f509bf5a2409465592db1fc826c46",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte is Friday's IBD Stock Of The Day. Shares are testing a trendline within a base. That would offer an early entry into the biotech..",
                "category": "company",
                "datetime": 1789750335,
                "headline": "IBD Stock Of The Day Eyes Buy Points As Investors Dig Into Its Pipeline"
              },
              {
                "id": 142252050,
                "url": "https://finnhub.io/api/news?id=8a29ce95b8561e45cc4eae2eca551ccca3c17ca7c92fdd223266bfff202193b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.",
                "category": "company",
                "datetime": 1789731968,
                "headline": "Dow Jones Futures: After S&P 500, Nasdaq Rebound, What's Next? Moderna, AMD, SpaceX Flash Buy Signals."
              },
              {
                "id": 142251199,
                "url": "https://finnhub.io/api/news?id=a581129efd1456cf0c04bbcd52a533fb0e0cec3f6e1787c33892f5e1d2478b14",
                "image": "https://www.chartmill.com/images/uploads/minervini_news_8825971f4b.webp",
                "source": "ChartMill",
                "related": "INCY",
                "summary": "INCY combines Minervini Trend Template strength, 93.53 RS, and high-growth momentum. Technical Rating 9, but watch resistance near 129.93 for breakout.",
                "category": "company",
                "datetime": 1789729273,
                "headline": "Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum"
              },
              {
                "id": 142250252,
                "url": "https://finnhub.io/api/news?id=34adaed45b12e382bfc23bef5a02b53d134a188f8fd2d03dc77212031e8e6135",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.",
                "category": "company",
                "datetime": 1789728962,
                "headline": "Dow Jones Futures Rise After Bullish S&P 500, Nasdaq Rebound; Moderna, AMD, SpaceX Flash Buy Signals"
              },
              {
                "id": 142236430,
                "url": "https://finnhub.io/api/news?id=1b353f221d269fb06c0864981159bf974df8dcf5f648a2490a0e7f238230c195",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.",
                "category": "company",
                "datetime": 1789700941,
                "headline": "Dow Jones Futures: S&P 500, Nasdaq Rebound Above Key Level; Moderna, AMD, SpaceX Flash Buy Signals"
              },
              {
                "id": 142232487,
                "url": "https://finnhub.io/api/news?id=bed0ef3889913874d68a6e92a2b05cc58de8c0d87d9dfc9067a9693b32aad3e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.",
                "category": "company",
                "datetime": 1789696144,
                "headline": "Dow Jones Futures Fall After S&P 500, Nasdaq Rebound Above Key Level; Moderna, AMD, SpaceX Flash Buy Signals"
              },
              {
                "id": 142233645,
                "url": "https://finnhub.io/api/news?id=628cdb077efa7dcbb14e295748e75d17a126177cf8c1528d4947d8259144ebe3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Mirum and Incyte are now awaiting the FDA’s decision on zilurgisertib, a once-a-day pill for an ultra-rare bone disease.",
                "category": "company",
                "datetime": 1789685045,
                "headline": "MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains?"
              },
              {
                "id": 142224040,
                "url": "https://finnhub.io/api/news?id=0c980ff08b24c8c18f83a9ff8e04d78ba6d1d8579182f39d9771f7189428fda3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.",
                "category": "company",
                "datetime": 1789645097,
                "headline": "3 Growth Stocks to Add to Your Roster"
              },
              {
                "id": 142225243,
                "url": "https://finnhub.io/api/news?id=d0573a7b47114c789f926d1ea0a14e1fb05e97d846ab26128a3e6da3c7cbaa88",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/17/Charles-Schwab.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "CNBC final trades: Pros picked Schwab, Cleveland-Cliffs, UnitedHealth and Incyte; shares posted mixed moves Wednesday.",
                "category": "company",
                "datetime": 1789630302,
                "headline": "Charles Schwab, UnitedHealth And Cleveland-Cliffs: CNBC’s ‘Final Trades’"
              },
              {
                "id": 142209442,
                "url": "https://finnhub.io/api/news?id=01434c6061042e370d190aeae26cbdd1dde460e5cefb2c5a281fbc29d5982136",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "Incyte (INCY) drew fresh attention after Ontario agreed to fund MINJUVI for relapsed or refractory follicular lymphoma through its FAST Program, giving eligible patients earlier access while reimbursement reviews continue. For context, Incyte’s share price has climbed 27.0% over the past 90 days and the year-to-date share price return is 23.0%. Meanwhile, the 1-year total shareholder return of 47.1% and 3-year total shareholder return of 106.6% point to momentum that long-term holders have...",
                "category": "company",
                "datetime": 1789611102,
                "headline": "Is Incyte (INCY) Undervalued After Ontario Backed MINJUVI Access?"
              },
              {
                "id": 142200639,
                "url": "https://finnhub.io/api/news?id=b5d523235573dcfeba3a034b33cd96fff4bafdc2078a47f853a6a557590b0058",
                "image": "",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "",
                "category": "company",
                "datetime": 1789588010,
                "headline": "Tracking Baker Brothers' Portfolio: Q2 2026 Update"
              },
              {
                "id": 142199262,
                "url": "https://finnhub.io/api/news?id=9f06b7c48f31066b68bce141e7de420b582718f18e7b044b6cb18222e476eba6",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte Corporation (INCY) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 12:20 PM EDTCompany ParticipantsWilliam Meury - CEO...",
                "category": "company",
                "datetime": 1789574498,
                "headline": "Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
              },
              {
                "id": 142225244,
                "url": "https://finnhub.io/api/news?id=70e4707785aff203ce7ee6009f9ce454f7bfb436536e44e1892ed02823842517",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/16/Tumor-Microenvironment-Concept-With-Canc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "INCY",
                "summary": "William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.",
                "category": "company",
                "datetime": 1789565932,
                "headline": "This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales"
              },
              {
                "id": 142197499,
                "url": "https://finnhub.io/api/news?id=a0ff66b6ef4e9b713fbe35e61a0980272fafb54317baeaf055a5718980e59b78",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2223338940/image_2223338940.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Mirum Pharmaceuticals is technically oversold but is likely to have more major drug pipeline catalysts occur in the coming months. Click for more on MIRM.",
                "category": "company",
                "datetime": 1789560721,
                "headline": "Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events"
              },
              {
                "id": 142186094,
                "url": "https://finnhub.io/api/news?id=b45ddb830214e435f9e6259735ec1b1e3e5239ea87fe9fbff66426061d513231",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "INCY",
                "summary": "A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.",
                "category": "company",
                "datetime": 1789544389,
                "headline": "1 Cash-Heavy Stock for Long-Term Investors and 2 We Ignore"
              },
              {
                "id": 142159413,
                "url": "https://finnhub.io/api/news?id=9940f11e00ef11b56fbaf4dd13b897e7b572f3bdadc1b454dd5583cd521952fa",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/964042876/image_964042876.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Damora Therapeutics targets myeloproliferative neoplasms with a pipeline led by DMR-001, now in Phase 1/1b trials. Learn why DMRA stock is a hold.",
                "category": "company",
                "datetime": 1789455910,
                "headline": "Damora Therapeutics: Potential Payday Is A Long Way Off"
              },
              {
                "id": 142157694,
                "url": "https://finnhub.io/api/news?id=64c36ae0193a4e2d634bcbbe22e26f06d8c709cc31f4aab7f4b4d42d143a974b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1493093301/image_1493093301.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "INCY",
                "summary": "Incyte (INCY) stock rated Sell: valuation assumes high pipeline success.",
                "category": "company",
                "datetime": 1789450454,
                "headline": "Incyte: Priced For Success, With No Margin Of Safety"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 58,
            "discarded_article_count": 47
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 11.5,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 0,
          "macdPoints": 0.8,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0,
            "vcp_reason": "Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 1676956.6666666667,
              "down_days": 6,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 1920270,
              "avg_vol_20": 1810205,
              "avg_vol_30": 1676956.6666666667,
              "range_pct_10": 0.11865454224419526,
              "range_pct_20": 0.18486801447867926,
              "range_pct_30": 0.19616844707336453,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.1450922007525537,
              "dist_to_20d_high": 0.12002796768178996,
              "down_shrink_days": 1,
              "breakout_level_20d": 128.72,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.6048604860486048
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 0.8,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 3.004237662223007,
              "turnoverUsdM": 219.79896248999998,
              "liquidityPoints": 0.4,
              "volatilityPoints": 0.7
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.INCY",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 106.4642,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 1,
              "rsi_score": 2.5,
              "macd_score": 1,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 6,
            "take_profit_price": 119.7355,
            "target_multiplier": 1.9,
            "technical_strength": 1.5,
            "take_profit_percent": 5.7
          },
          "positionPoints": 1.1,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 6.008475324446014,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 3.4029,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 4,
      "atr_pct": 3
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -52.76
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.3458
    },
    "kdj": {
      "d": 22.27,
      "j": 62.94,
      "k": 35.83,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 29.4
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": -18229913,
      "recentSlope": -419581.3,
      "previousSlope": -1021410
    },
    "rsi": 27.19,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 116.0183,
      "position": "SAR喺價上",
      "distancePct": 2.43,
      "previousTrend": "下降"
    },
    "ma50": 121.9402,
    "macd": {
      "macd": -3.4101562989040985,
      "trend": "看跌",
      "signal": -2.7980958995373584,
      "histogram": -0.6120603993667402
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 118.2565,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.06,
      "score": 6,
      "avgVolume": 1833789,
      "currentVolume": 1940487
    },
    "derived": {
      "ma20": 118.1165,
      "ma50": 121.9402,
      "prevClose": 111.57,
      "avgVolume10": 1878069,
      "avgVolume20": 1833789,
      "changePercent": 1.52,
      "avgVolumeForScore": 1833789
    },
    "ma_cross": {
      "ma20": 118.1165,
      "ma50": 121.9402,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 118.834,
      "prevMa50": 122.0708,
      "spreadPct": 3.14,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 106.2486,
      "upper": 129.9844,
      "position": "中間"
    },
    "rsi_short": 49.11,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.06
    }
  }
}

{
  "close": 113.27,
  "volume": 1940487,
  "changePercent": 1.52
}